LRTM2 Inhibitors
LRTM2 Inhibitors encompass a diverse group of chemical compounds that, while not directly targeting LRTM2, exert their inhibitory effects through various mechanisms that ultimately converge on the downregulation or functional inhibition of LRTM2. LRTM2 is involved in synaptic plasticity and function, and its activity is modulated through signaling pathways that control synaptic strength and plasticity. For example, Bisindolylmaleimide I, through its action on PKC, can inhibit the phosphorylation events that are crucial for maintaining synaptic strength, thereby indirectly inhibiting LRTM2 by impairing the synaptic signaling that regulates its activity. Similarly, NBQX's antagonism of AMPA receptors directly decreases excitatory neurotransmission, which is essential for LRTM2's role in synapse development and function. The reduction in excitatory signaling would logically lead to a decreased functional demand and subsequent downregulation of LRTM2.
On the other hand, compounds like BAPTA-AM and Thapsigargin disrupt intracellular calcium signaling, a key element in the regulation of synaptic plasticity and neuron excitability, processes in which LRTM2 is implicated.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a potent and selective inhibitor of Protein Kinase C (PKC). LRTM2 is known to be involved in synaptic function and plasticity. PKC plays a critical role in regulating synaptic strength. By inhibiting PKC, Bisindolylmaleimide I would impair synaptic signaling, subsequently leading to the downregulation of LRTM2's functional activity at the synapse. | ||||||
D-Cycloserine | 68-41-7 | sc-221470 sc-221470A sc-221470B sc-221470C | 200 mg 1 g 5 g 25 g | $27.00 $75.00 $139.00 $520.00 | 4 | |
D-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor. Since LRTM2 is implicated in synaptic processes, particularly those modulated by NMDA receptor activity, D-Cycloserine would indirectly inhibit LRTM2 by competing with full agonists, thereby dampening NMDAR-mediated synaptic activity. | ||||||
6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione | 118876-58-7 | sc-478080 | 5 mg | $70.00 | 1 | |
NBQX is a competitive antagonist of the AMPA receptor. LRTM2 is associated with excitatory synapse development and function. By blocking AMPA receptors, NBQX would lead to a decrease in excitatory neurotransmission, potentially downregulating LRTM2 activity due to reduced synaptic demand. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
BAPTA-AM chelates intracellular calcium, inhibiting calcium-dependent signaling, and thus indirectly inhibiting LRTM2's role in synaptic plasticity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits SERCA, leading to dysregulated calcium signaling pathways and potential inhibition of LRTM2-related synaptic plasticity processes. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 inhibits CaMKII, which is essential for synaptic plasticity; its inhibition may indirectly reduce LRTM2 activity associated with synaptic plasticity. | ||||||
Concanavalin A | 11028-71-0 | sc-203007 sc-203007A sc-203007B | 50 mg 250 mg 1 g | $117.00 $357.00 $928.00 | 17 | |
Concanavalin A binds to and cross-links glycoproteins. Binding to LRTM2 could sterically hinder its synaptic interactions, leading to functional inhibition. | ||||||